Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 706321 single rising dose in healthy male subjects
NCT03971695Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2019
- Primary completion
- Dec 2020
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of bi 706321 (13 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Percentage of Subjects With Drug-related Adverse Events up to 22 days, Area Under the Concentration-time Curve of BI 706321 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point at 168 hours and 1 more. Started Jun 2019; status: completed.
02
Drugs
bi 706321
Beyond the preview
Go deeper on NCT03971695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03971695.